As at May 2, 2024, the EXEL stock has a PE ratio of 34.56. This is based on the current EPS of $0.64 and the stock price of $22.12 per share. A decrease of 27% has been recorded in the P/E ratio compared to the average of 47.4 of the last 4 quarters.
The mean historical PE ratio of Exelixis over the last eight years is 59.97. The current 34.56 PE ratio is 42% below the historical average. In the past eight years, EXEL's PE ratio was at its highest in the Mar 2017 quarter at 722.33, with a price of $21.67 and an EPS of $0.03. The Dec 2018 quarter recorded the bottom point at 8.48, with a price of $19.67 and an EPS of $2.32.
Maximum annual increase: 235.44% in 2020
Maximum annual decrease: -85.49% in 2018
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 36.91 | 31.17% |
| 2022 | 28.14 | 12.38% |
| 2021 | 25.04 | -55.09% |
| 2020 | 55.75 | 235.44% |
| 2019 | 16.62 | 95.99% |
| 2018 | 8.48 | -85.49% |
| 2017 | 58.46 | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
EXEL's current P/E ratio is lower than the 3, 5 and 10-year averages.
EXEL's PE ratio is lower than its peer stocks MRK and PFE, but it is greater than JNJ's and AMGN's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 9.82 | $360.81B |
| AMGN Amgen Inc | 22.16 | $149.19B |
| EXEL Exelixis Inc | 34.56 | $6.44B |
| PFE Pfizer Inc | 72.89 | $156.42B |
| MRK Merck & Co Inc | 916.14 | $324.84B |
| BMY Bristol Myers Squibb Co | N/A | $88.58B |
| CRIS Curis Inc | N/A | $97.31M |
EXEL stock has a price to earnings ratio of 34.56 as of May 2, 2024.
The 3-year average PE ratio for EXEL stock is 37.23.
The 5-year average PE ratio for EXEL stock is 36.65.
In the last eight years, the Mar 2017 quarter recorded the highest quarterly PE ratio at 722.33.
EXEL's current price to earnings ratio is 42% below its 8-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (May 2, 2024), Exelixis's stock price is $22.12. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $0.64. Therefore, Exelixis's P/E ratio for today is 34.56. PE RATIO(34.56) = STOCK PRICE($22.12) / TTM EPS($0.64)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.